Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 5.12 (-0.58%)
CUE : 3.55 (-10.13%)
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 5.12 (-0.58%)
TCRX : 2.22 (-1.70%)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 5.12 (-0.58%)
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LUMO : 5.12 (-0.58%)
CSTL : 24.53 (-4.59%)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 5.12 (-0.58%)
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

LUMO : 5.12 (-0.58%)
IMRX : 6.21 (+4.64%)
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?

Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

AMYT : 7.03 (-1.68%)
LUMO : 5.12 (-0.58%)
Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...

LUMO : 5.12 (-0.58%)
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA...

LUMO : 5.12 (-0.58%)
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA...

LUMO : 5.12 (-0.58%)

Barchart Exclusives

EPA Proposals Would Bring Major Changes to the U.S. Biofuel Efforts
Last Week’s Moves Corn 640-0 (-4.92%) | Soybeans 1438-6 (-1.41%) | SRW Wheat 737-2 (-5.06%) KC Wheat 846-6 (-5.28%) | Live Cattle 156.150 (+0.97%) | Lean Hogs 90.875 (+7.11%) _________________________________________________________________________________________ Welcome to your weekly agriculture report, where we cover everything you’ll need to know for the week ahead. This week,... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar